Sign up to save your podcasts
Or
Share Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.
CME information and select publications here.
View all episodes
By Dr. Neil Love
4.9
5656 ratings
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.
CME information and select publications here.
More shows like Oncology Today with Dr Neil Love
View all
JAMA Editors' Summary
138 Listeners
Gastrointestinal Cancer Update
17 Listeners
Lung Cancer Update
30 Listeners
Prostate Cancer Update
13 Listeners
Breast Cancer Update
71 Listeners
Gynecologic Oncology Update
13 Listeners
Hematologic Oncology Update
76 Listeners
Dermatologic Oncology Update
0 Listeners
NEJM This Week
322 Listeners
Research To Practice | Oncology Videos
116 Listeners
JAMA Clinical Reviews
499 Listeners
ASCO Daily News
57 Listeners
The Curbsiders Internal Medicine Podcast
3,331 Listeners
The ONS Podcast
200 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
366 Listeners
Two Onc Docs
185 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners